ACOG published a Clinical Practice Update on 25 August replacing its 2019 Committee Opinion on opportunistic salpingectomy. It further supports complete, bilateral removal of the fallopian tubes at the time of obstetric and gynaecological surgery as a strategy for primary prevention of epithelial ovarian cancer, and it supports making salpingectomy available during non-gynaecological abdominopelvic operations.
The rationale is that many high-grade serous cancers are now understood to arise in the fallopian tube rather than the ovary. Removing the tubes while conserving the ovaries keeps ovarian hormone production. For women requesting permanent contraception, including at caesarean birth, bilateral salpingectomy rather than tubal ligation offers contraception with a likely added cancer-prevention benefit.
The practical change is in the consent conversation and the theatre list. Women having a hysterectomy for benign disease, a caesarean with sterilisation, or a general surgical abdominal operation where the tubes are accessible, may be offered salpingectomy if they have completed childbearing. In India, where tubal ligation remains a common route to permanent contraception, this is worth weighing against operative time and local practice. The update is American guidance and does not address Indian practice directly.
- Offer bilateral salpingectomy instead of tubal ligation when a woman requests permanent contraception, including at caesarean birth.
- Discuss salpingectomy with ovarian conservation before benign hysterectomy in women who have completed childbearing.
- Talk with general surgical and urology colleagues about offering salpingectomy during other abdominopelvic operations where safe.
- Make clear in consent that salpingectomy is permanent and is not a substitute for risk-reducing salpingo-oophorectomy in BRCA carriers.
- Record the reason for leaving tubes in place when salpingectomy was technically possible but not done.
Why it matters
It turns operations already on the list into a primary prevention opportunity for a cancer with no effective screening test.
Don't overread it
This is a professional practice update, not a new trial; the long-term reduction in ovarian cancer incidence is still being measured.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free